公开(公告)号：EP1685112B1

公开(公告)日：2011-07-20

申请号：EP04790836.3

申请日：2004-10-26

申请人： Bayer Schering Pharma Aktiengesellschaft

发明人： BOUCHON, Axel ,  DIEDRICHS, Nicole ,  HERMANN, Achim ,  LUSTIG, Klemens ,  MEIER, Heinrich ,  PERNERSTORFER, Josef ,  REISSMÜLLER, Elke ,  MOGI, Muneto ,  FUJISHIMA, Hiroshi ,  TAJIMI, Masaomi, 1-8-17, Sakuragaoka, Seika-cho ,  YAMAMOTO, Noriyuki

IPC分类号： C07D215/00

CPC分类号： C07D215/38

摘要： This invention relates to tetrahydro quinolinylurea derivatives (I) and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-quinolinylurea ueri votive (J.) of the present invention has vanilloid receptor (VRl) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VRl activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor oeractivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), beniyn proscatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).

摘要翻译： 本发明涉及可用作药物制剂活性成分的四氢喹啉基脲衍生物（Ⅰ）及其盐。 本发明的四氢喹啉基尿酸还原剂（J.）具有类香草素受体（VR1）拮抗活性，并且可用于预防和治疗与VR1活性相关的疾病，特别是用于治疗泌尿科疾病或病症， 如逼尿肌过度活动（膀胱活动过度），尿失禁，神经原性逼尿肌过度活动（逼尿肌反射过度），特发性逼尿肌过度活动（逼尿肌不稳定），beniyn前列腺增生和下尿路症状; 慢性疼痛，神经性疼痛，术后疼痛，类风湿性关节炎疼痛，神经痛，神经病，痛觉，神经损伤，局部缺血，神经变性，中风和炎症如哮喘和慢性阻塞性肺（气道）疾病（COPD）。

公开(公告)号：EP1411932B1

公开(公告)日：2010-02-10

申请号：EP02738154.0

申请日：2002-06-07

申请人： Bayer Schering Pharma Aktiengesellschaft

发明人： STRAUB, Alexander ,  LAMPE, Thomas ,  PERNERSTORFER, Josef ,  PERZBORN, Elisabeth ,  POHLMANN, Jens ,  RÖHRIG, Susanne ,  SCHLEMMER, Karl-Heinz

IPC分类号： A61K31/422 ,  A61K31/435

CPC分类号： A61K31/422 ,  A61K31/421 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

摘要： The invention relates to combinations of A) oxazolidinones of formula (I) and B) other active ingredients, to a method for producing said combinations and to the use thereof as medicaments, in particular for the treatment and/or prophylaxis of thrombo-embolic diseases.

公开(公告)号：EP1720857B1

公开(公告)日：2011-07-13

申请号：EP05701362.5

申请日：2005-02-05

申请人： Bayer Schering Pharma Aktiengesellschaft

发明人： GIELEN-HAERTWIG, Heike ,  ALBRECHT, Barbara ,  BAUSER, Marcus ,  KELDENICH, Jörg ,  LI, Volkhart ,  PERNERSTORFER, Josef ,  SCHLEMMER, Karl-Heinz ,  TELAN, Leila

IPC分类号： C07D401/06 ,  C07D211/76 ,  A61K31/4422

CPC分类号： C07D487/04 ,  C07D211/90 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D409/12

摘要： The invention relates to novel dihydropyridinone derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.

摘要翻译： 本发明涉及新的二氢吡啶酮衍生物，其制备方法及其在药物中的用途，特别是用于治疗慢性阻塞性肺病，急性冠状动脉综合征，急性心肌梗塞和心力衰竭发展。